Profiel
Robert E.
Winkler worked as Vice President of Clinical Research & Development at Array BioPharma, Inc. He then worked as Vice President of Clinical Research & Operations at Amicus Therapeutics, Inc. from 2011 to 2013.
In 2018, he became the Chief Medical Officer at Zentalis Pharmaceuticals, Inc. Dr. Winkler received his undergraduate and doctorate degrees from The Hebrew University Hadassah Medical School.
Eerdere bekende functies van Robert E. Winkler
| Bedrijven | Functie | Einde |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 19-03-2020 |
| AMICUS THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2013 |
| ARRAY TECHNOLOGIES, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Robert E. Winkler
| The Hebrew University Hadassah Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
